CAJ | 학술논문

目的评价瞬时弹性记录仪(FibroScan R )实施受控衰减参数(CAP)无创定量诊断脂肪肝的影响因素及重复性.方法使用新型FibroScan-502机型及M探头对非酒精性脂肪性肝病(NAFLD)患者及对照人群进行肝脏脂肪含量(CAP值)测定.应用组内相关系数(ICC)评价重复测量的变异程度.结果169例NAFLD患者和59例对照人群接受FibroScan R 检查,其中200例(87.7%)完成有效测量;肥胖组检查成功率显著低于体重正常组[75.0%(33/44)对93.9%(77/82),x2=9.548,P=0.02],女性、高龄和中心性肥胖者影响检查成功率;NAFLD组CAP值显著高于对照组(291.1±54.0dB/m对216.4±43.3dB/m,P<0.01);63例NAFLD患者进行CAP重复性测量提示同一操作者ICC为0.848(95%可信区间为0.761~0.905,P<0.01),不同操作者ICC为0.718(95%可信区间为0.607~0.896, P<0.01).结论 FibroScan R 新参数CAP可用于脂肪肝的无创诊断,但肥胖症影响其测量成功率.
목적평개순시탄성기록의(FibroScan R )실시수공쇠감삼수(CAP)무창정량진단지방간적영향인소급중복성.방법사용신형FibroScan-502궤형급M탐두대비주정성지방성간병(NAFLD)환자급대조인군진행간장지방함량(CAP치)측정.응용조내상관계수(ICC)평개중복측량적변이정도.결과169례NAFLD환자화59례대조인군접수FibroScan R 검사,기중200례(87.7%)완성유효측량;비반조검사성공솔현저저우체중정상조[75.0%(33/44)대93.9%(77/82),x2=9.548,P=0.02],녀성、고령화중심성비반자영향검사성공솔;NAFLD조CAP치현저고우대조조(291.1±54.0dB/m대216.4±43.3dB/m,P<0.01);63례NAFLD환자진행CAP중복성측량제시동일조작자ICC위0.848(95%가신구간위0.761~0.905,P<0.01),불동조작자ICC위0.718(95%가신구간위0.607~0.896, P<0.01).결론 FibroScan R 신삼수CAP가용우지방간적무창진단,단비반증영향기측량성공솔.
Objective To evaluate the influencing factors and reproducibility of controlled attenuation parameters (CAP)measurement of fatty liver using FibroScan R . Methods Patients with non-alcohol fatty liver disease(NAFLD)and normal controls were recruited to complete the CAP measurement with new FibroScan-502 and M probe. In NAFLD groups,some subjects were repeatedly checked-up by the same or different operator. Intraclass correlation coefficient (ICC)was used to evaluate the reproducibility of the operation. Results A total of 228 subjects were recruited, and 200 subjects(87.7%)got the valid measurement;the success rates in normal and obese persons were 93.9%(77/82)and 75.0%(33/44,x2=9.548,P=0.02),respectively;female,senior and obese persons had lower success of examination;CAP values in NAFLD group was 291.1±54.0 dB/m,significantly higher than that in control groups(216.4±43.3dB/m,P<0.01);The ICC was 0.848(95% CI 0.761~0.905,P<0.01)with same operator and 0.718 (95% CI 0.607~0.896,P<0.01)with different operator. Conclusion The CAP can be used for non-invasive diagnosis of fatty liver,with a good reproducibility.